Olinger Margaret 4
4 · Amylyx Pharmaceuticals, Inc. · Filed Jul 14, 2023
Insider Transaction Report
Form 4
Olinger Margaret
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-07-12$0.37/sh+20,000$7,400→ 251,108 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-07-12−20,000→ 69,577 totalExercise: $0.37Exp: 2029-05-13→ Common Stock (20,000 underlying)
Footnotes (1)
- [F1]As of the date of this filing, 67,156 shares subject to the option are vested and exercisable. 2,421 shares subject to such option vest and become exercisable in substantially equal monthly installments until August 13, 2023.